The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

Bibliography

• Parkin DM. International variation. Oncogene 2004;23:6329-40
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Ward E. Worldwide trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009l;18:1688-94
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-78
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J Clin Oncol 1998;16:301-8
   PubMedGoogle Scholar
• Van Cutsem E, Twelves C, Cassidy J, Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G, Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrrhonen S, James RD, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-18
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Oza RH, Bigelow JD, Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III Trial. J Clin Oncol 2003;21:2059-69
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargeant DJ, Morton RF, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 2007;25:4779-86
   PubMed Web of Science ®Google Scholar
• Fuchs CS. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluorpyrimidines in first line treatment of metastatic colorectal cancer: update from BICC-C trial. J Clin Oncol 2008;26:689-90
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, Maillard JA, Kahn MJ, Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-150
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Mamounas ES, Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-9
   PubMed Web of Science ®Google Scholar
• Andre T, Colin P, Louvet C, Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003;21:2896-903
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D, Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007;25:3456-61
   PubMed Web of Science ®Google Scholar
• Ychou M, Hohenberger W, Thezenas S, A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009;20:1964-70
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Liabianca R, Bodoky G, Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-25
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Moundedji-Boudief L, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haest 1997;78:627-7
   PubMedGoogle Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10
   PubMed Web of Science ®Google Scholar
• Kerbal RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312:549-60
   PubMed Web of Science ®Google Scholar
• Takeshi Y, Kitadai Y, Bucana CD, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Ferraraccio F, Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-9
   PubMed Web of Science ®Google Scholar
• Liang WC, Wu X, Peale VF, Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281:951-61
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Conner SJ, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Houck K, The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64
   PubMedGoogle Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz G, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon MS, Holmgren J, Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-6
   PubMed Web of Science ®Google Scholar
• Kabbinivar F, Hurwitz HI, Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65: 2003
   PubMed Web of Science ®Google Scholar
• Kabbinivar FF, Schultz J, McCleod M. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Wolmark N, Yothers G, O'Connell MJ, A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 [abstract LBA4]. J Clin Oncol 2009;27:18s
   Web of Science ®Google Scholar
• Roche provides results on Avastin® in adjuvant colon cancer: second phase III study does not meet primary endpoint. Investor Updates. Basel, Switzerland, September 18, 2010. Available from: http://www.roche.com/investors/ir_update/inv-update-2010-09-18b.htm= [Last accessed 30 October 2010]
   Google Scholar
• Ranpura V, Hapani V, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncologica 2010;49:287-97
   PubMed Web of Science ®Google Scholar
• Rani Nalluri S, Chu D, Keresztes R. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab: a Meta-analysis. JAMA 2008;300:2277-85
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ, Initial safety report of NSABP-C08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27:3385-90
   PubMed Web of Science ®Google Scholar
• Okines A, del Puerto O, Cunningham D, Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8
   PubMed Web of Science ®Google Scholar
• Kozloff M, Ulcickas Yood M, Berlin J, Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the Brite Observational Cohort Study. Oncologist 2009;14:862-70
   PubMed Web of Science ®Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10:559-68
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev 2008;8:592-603
   Google Scholar
• Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharm Sci 2009;30:624-30
   PubMed Web of Science ®Google Scholar
• Francia G, Emmenegger U, Kerbel R. Tumor-associated fibroblasts as ‘Trojan horse’ mediators of resistance to anti-VEGF therapy. Cancer Cell 2009;15:3-34
   PubMed Web of Science ®Google Scholar
• Cacheux W, Boisserie T, Staudacher L, Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 2008;19:1659-61
   PubMed Web of Science ®Google Scholar
• Miles D, Ellis LM, Reardon DA. Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol 2010;11:809-11
   PubMed Web of Science ®Google Scholar
• Ebos JML, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9
   PubMed Web of Science ®Google Scholar
• Stockmann C, Doedens A, Weidemann A, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456:814-18
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9
   PubMed Web of Science ®Google Scholar
• Ince WL, Jubb AM, Holden SN, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97:981-9
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HI, Bai W, Impact of vascular endothelial growth factor-A expression thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-27
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8
   PubMed Web of Science ®Google Scholar
• Schultheis AM, Lurje G, Rhodes KE, Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-63
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM, Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study. J Clin Oncol 2008;26:5326-34
   PubMed Web of Science ®Google Scholar